Clinical Trial Update: Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection [Phase 2]

View source ↗

Summary

Phase 2 open-label extension trial update for CP101 (Oral Full-Spectrum Microbiota) in recurrent Clostridium difficile infection; results were posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile Infection

Drugs mentioned

• CP101

Snippet

Sponsor: Finch Research and Development LLC. | Conditions: Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection | Phase 2 | Status: COMPLETED | Results posted: 2022-08-30